Acute intermittent porphyria (AIP) is a hepatic metabolic disease that results from haplo-insufficient activity of porphobilinogen deaminase (PBGD). The dominant clinical feature is acute intermittent attacks when hepatic heme synthesis is activated by endocrine or exogenous factors. Gene therapy vectors over-expressing PBGD protein in the liver offers potential as a cure for AIP. Here, we developed a helper-dependent adenovirus (HDA) encoding human PBGD (hPBGD) and assessed its therapeutic efficacy in a murine model of AIP. Intravenous or intrahepatic administration of HDA-hPBGD to AIP mice resulted in a sustained hepatic hPBGD expression in a dose-dependent manner. Intrahepatic administration conveyed full protection against induced porphyria attacks at a significantly lower viral dose than intravenous injection. Transgenic hPBGD accumulated only in the cytosol of hepatocytes as the endogenous protein. Characterization of PBGD-deficient mouse strains revealed that a strong PBGD deficiency causes the chronic disturbance of cytosolic and endoplasmic reticulum folding machineries. This disturbance was completely restored over time by the over-expression of hPBGD. HDA-hPBGD is a promising vector that protects against porphyria attacks and resolves the chronic folding stress associated with low levels of PBGD activity.
INTRODUCTION
Acute intermittent porphyria (AIP, OMIM 176000) is a rare inborn error of the heme synthesis pathway caused by halfnormal activity of the third enzyme of the route, porphobilinogen deaminase (EC 4.3.1.8; PBGD). AIP is clinically characterized by acute attacks when hepatic heme synthesis is activated by endocrine and environmental factors, caloric restriction or intercurrent infections (1) (2) (3) (4) . Severe and recurrent attacks are associated with motor neuropathy (5) . Recurrent attacks are a life-threatening condition that can be cured only by allogenic liver transplantation (6, 7) . Nevertheless, transplantation suffers from limited availability of donors; requires life-long immunosuppression and is associated with mortality and morbility and high rate of hepatic artery thrombosis (8) . The observation that liver transplantation cannot reverse the effect of previous neuronal damage supports the need to implement therapeutic procedures before severe neurological symptoms appear or become irreversible.
Liver gene therapy mediated by recombinant adeno-associated viral (rAAV) vectors has demonstrated long-term protection against biochemical induced acute attacks in a predictive mouse model for AIP (9, 10) . After rAAV administration, most transgene expression results from extra chromosomal vector genomes that persist as concatemeric structures (11) . This rate of integration into the genome of the host cell reduces the risk of insertional mutagenesis but entails the dilution of the vector and its therapeutic effect with the natural division of hepatocytes. As a consequence, maintenance of the therapeutic effect throughout the life of the patient would require successive re-administration of the vector. However, host immunity against viral vector precludes re-administration (12) (13) (14) . Thus, one option to circumvent anti-vector immunity could be alternating administration of different vectors carrying the same transgene. Helperdependent adenoviruses (HDAs) are vectors that have demonstrated high efficiency in liver gene therapy (15) . They exhibit high tropism for the liver and are able to infect and achieve the maximum expression of the transgene in less than 48 h (16) . HDA vector genomes persist as linear monomers in murine hepatocytes (17, 18) A single administration of a HDA resulted in long-term transgene expression in different mouse model of genetic diseases (19) , rats (20) , dogs and non-human primates (21) . Furthermore, although they conserve the wild-type capsid, they lack all the genes for viral gene expression, which makes them less immunogenic than first generation adenoviruses (22) .
In this study, we have developed a novel HDA encoding human PBGD (hPBGD) in order to induce stable PBGD expression in the liver and to prevent the accumulation of toxic porphyrin precursors, which is associated with acute attacks and motor neuropathy. To optimize the delivery of HDA-hPBGD to hepatocytes, we injected the vector by intrahepatic or intravenous routes. Then, we measured hPBGD activity and its subcellular localization in hepatocytes. Proper localization of the recombinant PBGD protein is relevant for gene therapy safety because its abnormal secretion to serum could induce the activation of the immune response against the transgene. On the other hand, a nuclear role of PBGD related to cell transformation and differentiation has been proposed (23) . Therefore, taking advantage of the efficient transduction of HDA vectors in vitro, the subcellular localization of the transgenic protein was observed and its effect on cell growth was assessed.
Protein over-expression may compromise the folding capacity of the cell and generate a situation of folding stress (24) . Heat shock proteins (HSPs) are induced in the cell in response to unbalanced protein synthesis, metabolic stress, oxidative stress and other phenomenon (25) to restore folding and prevent the propagation of stress. Under specific chronic cytosolic stresses, misfolded proteins can saturate the folding/ protein turnover machineries and form aggregates. In these situations, stress might propagate to other compartments, such as the endoplasmic reticulum (ER), causing the activation of ER stress responses (26, 27) . To assess the impact of hPBGD over-expression on the protein homeostasis of hepatocytes, we monitored the levels of cytosolic and ER chaperones in an AIP murine model treated with HDA-hPBGD.
The aim of the study was to develop a HDA vector encoding transgenic PBGD and establish a proof of principle for gene therapy for AIP. Both intravenous (i.v.) and intrahepatic (IH) administration will be tested with regards to therapeutic efficiency, to subcellular localization of transgenic hPBGD protein and to the impact of its over-expression on homeostasis of protein folding.
RESULTS

HDA-hPBGD expression in the liver protects against acute attack in AIP mice
The efficacy of the HDA encoding the hPBGD protein was assayed in female and male AIP mice after i.v. injection of a dose of 1.5 × 10 10 infective units (iu)/kg ( Fig. 1) . In order to address the therapeutic effect of the HDA-hPBGD vector at that dose, AIP mice were challenged with phenobarbital to induce biochemical attacks once a month during 3 months. After each attack, excretion levels of aminolevulinic acid (ALA) and porphobilinogen (PBG) porphyrin precursors were measured in urine. In those mice injected with saline, a significant increase in ALA and PBG was detected from baseline levels after the biochemical attacks in both males and females ( Fig. 1A-B) . In those mice injected with the therapeutic vector, no significant differences in precursor excretion were detected between baseline levels and those after each phenobarbital challenge (Fig. 1A-B) . These data suggest total protection against the phenobarbital induced attack at the dose given. Groups of mice were sacrificed 1 and 3 months after the injection and PBGD enzymatic activity was measured. The dose of 1.5 × 10 10 iu/kg provided an elevated PBGD expression, which was sustained over the duration of the experiment. No gender differences were observed after i.v. administration (Fig. 1C) .
Intrahepatic injection of HDA-hPBGD allows reduction of vector dose necessary for total protection against acute attacks
One aim of this study was to compare different routes of administration for HDA-hPBGD. Thus, one group of male AIP mice received an IH injection of 2 × 10 9 iu/kg, while another cohort of male AIP mice was i.v. injected with the same dose. Both groups were challenged with phenobarbital to induce a biochemical attack 2 weeks after injection. As expected, AIP control animals showed a high urinary increase in ALA and PBG ( Fig. 2A) . Also, animals receiving the vector by i.v. administration showed an increased concentration of porphyrin precursor in urine. However, the same dose injected by the IH route resulted in full protection against the induced biochemical attack (Fig. 2A) . Subsequent phenobarbital challenge performed at 8 and 12 weeks post-injection showed the same pattern of porphyrin precursor excretion (data not shown). After sacrifice, only a slight increase in PBGD activity was detected in the liver of those mice i.v. injected (Fig. 2B ), which correlated with urinary porphyrin precursor accumulation. These results indicate that the injected dose was under the limit of total protection against the acute attack when administered systemically. Nevertheless, mice injected directly in the liver with HDA-hPBGD showed a significant increase in PBGD activity compared with AIP control mice (Fig. 2B) . Moreover, the activity achieved was similar in the injected liver lobe and another non-injected liver lobe in the animals (Fig. 2B) . The same results were obtained in female AIP mice (data not shown). Transgene expression in the injected and uninjected liver lobes was confirmed by immunoblot assay (Fig. 2C ) and immunohistochemistry of hPBGD (Fig. 2D) . The liver was preferentially transduced after intravenous or intrahepatic administration of HDA-hPBGD. Quantitation of proviral DNA load using realtime quantitative PCR confirmed its liver tropism over the rest of the organs (Fig. 3) . PBGD activity measured in other transduced organs confirmed the lack of transgene expression outside of the liver (data not shown) since a hepatic promoter was used.
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Human Molecular Genetics, 2013, Vol. 22, No. 14 At the doses injected, the administration of HDA vector resulted in an early increase of serum concentrations of interleukin-6 (Supplementary Material, Fig. S1 ) indicating transient activation of the innate immune system. Since mice injected with the IH route received 10 times less viral vector than animals treated intravenously, a further reduction in serum interleukin-6 levels might have been expected. However, laparotomy also induces a robust acute innate response and we cannot differentiate the contribution of viral administration to the innate immune response activation. We also observed signs of moderate liver damage (transient increases in transaminases), but these changes never reached signs of liver dysfunction (Supplementary Material, Fig. S1 ).
Intrahepatic administration of 2 3 10 9 iu/kg was the minimum effective dose for full protection against induced attack in porphyria mice
In order to assess the minimum dose to obtain full protection against biochemical induction of an acute attack, a dose of Human Molecular Genetics, 2013, Vol. 22, No. 14 2931
1.3 × 10 9 iu/kg was administered in AIP male mice via the IH route. As expected, a dose-dependent increase in transgene expression was observed in mice after intrahepatic administration (Fig. 2B) . A lower dose produced an important protection against acute attack, as measured by weak porphyrin precursor excretion after phenobarbital challenge 
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Human Molecular Genetics, 2013, Vol. 22, No. 14 ( Fig. 2A ), although this protection was not as complete as the one observed in those animals receiving an IH dose of 2 × 10 9 iu/kg.
The synthesis of hPBGD is produced exclusively in the cytoplasm and is not detected in the nucleus or organelles
Liver samples from two AIP mice injected with 1.5 × 10 10 iu/kg and one AIP control mouse were homogenized and fractionated in subcellular compartments. Western blot analysis showed that the murine PBGD as well as transgenic hPBGD were only present in the cytoplasm of hepatocytes (Fig. 4A) . No signal was detected in organelles or in the nucleus (Fig. 4A) .
Confocal microscopy analysis of the Huh7 cell transduced with HDA-hPBGD confirmed that transgenic hPBGD was present at detectable levels in the cytoplasm but not in the nucleus or other organelles ( Fig. 4B-C) . In order to eliminate a possible effect of the over-expressed hPBGD on proliferation, a colorimetric MTT assay was carried out on Huh7 cells. No differences were detected between the non-infected cells and those infected with serial dilutions of the vector from 10
21 to 10 24 (data not shown). These results suggest that over-expressed hPBGD localized in the cytoplasm and ruled out any nuclear activity of the transgene in proliferation.
In order to address a possible secretion of the overexpressed protein, PBGD enzymatic activity and immunoblot assays were performed in the serum of transduced AIP mice. None of the AIP mice injected with HDA-hPBGD showed detectable levels of PBGD protein in the serum. A calibration curve was plotted with known quantities of purified PBGD protein in serum from uninjected mice and we were able to detect PBGD activity in quantities of 1 ng in the reaction mix (0.1 mg/ml of serum). Extrahepatic PBGD was indirectly assayed by determination of neutralizing antibodies in the serum of the AIP mice. As observed by western blot analysis, the antibodies present in the serum of the injected mice bound to the adenoviral fiber of the capsid but did not bind to the hPBGD (Fig. 4D ). These data suggest that the transgenic protein was not released outside the cell or was in very small amounts that are unable to trigger any humoral immune response in C57BL/6j background.
AIP mice show elevated expression of cytoplasmic chaperones compared with wild-type mice
The folding of cytoplasmic proteins is controlled by a dedicated group of HSPs where the most prominent components are HSP70 and HSP90. The levels of the cytosolic protein folding machinery are adjusted to need transcriptionally by the Heat Shock Factor 1 transcription factor (HSF1). To determine whether folding of over-expressed hPBGD may compromise cytoplasmic protein folding homeostasis, we analyzed cytoplasmic and ER stress in AIP mice (Fig. 5) . We measured baseline expression of HSP70 in wild-type mice and T1, T2 and AIP porphyric strains which have decreased hepatic PBGD activity of 67, 55 and 33%, respectively, when compared with wild-type mice. Figure 5A shows a significant elevation of the expression of HSP70 in AIP mice. Nonetheless, no differences were observed between T1 or T2 and wild-type mice, indicating that the origin of the folding disturbances in AIP mice is not caused by the presence of the mutated PBGD protein. Our assays suggested that marked PBGD deficiency in AIP mice (below 50% of normal activity) interfere with protein folding machinery. Thus, folding stress might be caused by limited heme synthesis in the liver of AIP animals (28) and/or the slight , where Ct is the point at which the fluorescence rises appreciably above background fluorescence. Data are shown as mean + SD. HDA, helper-dependent adenovirus.
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Human Molecular Genetics, 2013, Vol. 22, No. 14 accumulation of porphyrin precursors as reported in these mice (29, 30) . In order to ascertain whether the folding machinery was further disturbed by the increased porphyrin precursor levels during provoked crisis, phenobarbital challenge was performed in AIP mice (Supplementary Material, Fig. S2 ).
As a control group, we applied the challenge to AIP mice treated with 1.5 × 10 10 iu/kg of HDA-hPBGD where the high transgene PBGD over-expression protects against porphyrin precursor accumulation. Supplementary Material, Figure S2 shows that both groups of AIP mice over-express HSP70, suggesting that phenobarbital per se is able to induce folding stress independently of the levels of porphyrin precursors or PBGD over-expression. Supporting this notion, Narjoz et al. (31) observed endoplasmatic reticulum stress caused by cytochrome overexpression in human hepatoma cells after phenobarbital treatment. Altogether, we cannot Human Molecular Genetics, 2013, Vol. 22, No. 14 2935 rule out the possibility that low-level accumulation of porphyrin precursors contributes to the folding stress in porphyria mice. Since folding stress is detected in the absence of induced attacks in this model of porphyria and phenobarbital treatment interferes with the folding machinery itself, the following analyses were conducted in the absence of phenobarbital. It has been previously reported that cytoplasmic and the ER folding machineries are connected in order to better respond to protein damage (25) . Deficiencies in protein folding in the lumen of the ER cause the activation of an intracellular signaling pathway-the unfolded protein response (UPR)-that initiates a transcriptional program to restore ER folding capacity (32) . A key step in UPR signaling is the nonconventional splicing of the mRNA encoding the transcription factor XBP1. The cytosolic splicing of XBP1 mRNA, induced by ER stress, allows the translation of the active transcription factor, XBP1s which, in turn, induce the transcription of a vast set of genes, including ER chaperones. In order to evaluate UPR activation in AIP mice, we calculated the levels of XBP1 mRNA splicing as the ratio of spliced XBP1 (sXBP1) versus total XBP1 (tXBP1) mRNA in the liver of treated or untreated AIP and WT mice (Fig. 5B) .
Metabolic correction by HDA-hPBGD normalizes the levels of cytoplasmic and ER chaperones of AIP mice HSP70 expression was analyzed at different times in AIP mice that were i.v. injected with 1.5 × 10 10 iu/kg and 2 × 10 9 iu/kg or IH with 2 × 10 9 iu/kg. Only mice that were i.v. injected showed a significant increase in the cytoplasmic stress after injection (Fig. 5C ). This increase was independent of the vector dose or hPBGD over-expression. HSP70 over-expression was maintained 1 month after i.v. administration and then decreased to wild-type levels (Fig. 5D ). On the other hand, AIP mice that received the HDA vector directly in the liver did not show any increase in HSP70 mRNA. In addition, normalization of HSP70 expression to wild-type levels was faster compared with those mice i.v. injected (Fig. 5D) . The same results were obtained when HSP90b levels were measured (Fig. 5E) .
As observed for the cytosolic chaperones, we detected a significant increase in the levels of XBP1s mRNA and XBP1 splicing ratio in AIP mice. Again, there was an elevation of sXBP1 only in those mice receiving the HDA vector by the i.v. route (Fig. 5F ). This increase subsided after 2 weeks and the levels of stress were reduced to the values observed in wild-type mice. AIP mice IH injected did not show the early ER stress activation and reached wild-type values faster than those i.v. injected (Fig. 5F) . Therefore, the increased folding stress observed both in the cytosol and ER of AIP hepatocytes can be normalized after gene therapy with HDA-hPBGD.
DISCUSSION
The administration of HDA vectors by both i.v. and IH injection demonstrated its therapeutic efficiency in a murine model of AIP. After a single injection of HDA-hPBGD, transgene expression remained unmodified in AIP mice during the 3-month period of the study. However, when first generation adenoviral vectors encoding PBGD were tested in mice (33) , expression lasted for 30 days and then disappeared due to the immune response probably against the vector or the CMV promoter. The use of a hepatic-specific promoter in our HDA vector avoids this silencing and limits transgene expression to the liver. Furthermore, HDA vectors lack all the genes for viral gene expression that attenuate adaptive immune response.
However, systemic administration of HDA vectors leads to an acute response in a dose-dependent manner, indicating that the innate immune system primarily recognizes the wild-type adenoviral capsid (34, 35) . One way to reduce the adenoviral dose is by changing the method of administration from i.v. to IH (36) . Complete protection against biochemical induced attacks was achieved in AIP mice i.v. injected with 1.5 × 10 10 iu HDAhPBGD/kg. Nevertheless, IH administration allows reduction of the dose of vector while at the same time maintaining the same transduction efficacy. In our case, i.v. administration of 2 × 10 9 iu/kg constituted a subtherapeutic dose, whereas IH administration of the same dose resulted in full protection of the AIP mice. In our model, a lower dose administered intrahepatically (1.3 × 10 9 iu/kg) induced an important protection against the acute attack, although it is not as complete as that observed with the dose of 2 × 10 9 iu/kg IH. No gender differences were detected in liver transduction in either i.v. or IH administration.
Of interest, our research provides evidence that vector administration in a single liver lobe leads to expression of the transgene in the whole liver. How HDA vector spreads to neighboring liver lobes is unclear. One plausible explanation for the re-circulation of the vector is that, given the high levels of vascularization of the liver, HDA used the vascular circuit to reach other lobes. In agreement with this idea, we can detect virus spread to other organs after intrahepatic administration. This effect is observed in small experimental animals. According to this hypothesis, those liver lobes from big experimental animal (i.e. woodchucks and non-human primates) far from the injection point would receive lower amounts of virus and transduction after intrahepatic HDA delivery. This observation was previously reported in woodchucks after intrahepatic administration of a HDA-IL12, where the biological activity of the transgene was higher in the injected lobe when compared with in the remaining lobes (37) .
Since it is necessary to express a high amount of transgene in order to obtain a high degree of protection, we were concerned about the location of over-expressed hPBGD. Nevertheless, cellular fractionation and posterior detection of hPBGD in different cellular compartments, including the nucleus, did not show protein to be binding to membranes or to be present in any compartment other than the cytoplasm in mice injected with the highest dose (1.5 × 10 10 iu/kg). In vitro experiments where cells were infected with higher doses than those used in mice confirmed proper cytoplasmic location of the PBGD protein. In addition, we failed to detect any trace of the recombinant PBGD protein or neutralizing antibodies against human PBGD in the serum of these mice. This result suggests that the protein is not secreted or secreted in small amounts insufficient to generate neutralizing antibodies against the transgenic PBGD in this mouse strain.
Heat shock chaperones maintain protein folding homeostasis at the cytoplasm. Therefore, the expression of an aberrant
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Human Molecular Genetics, 2013, Vol. 22, No. 14 PBGD protein or the over-expression of hPBGD in the cytoplasm could be affecting their normal activity. The analysis of HSP70 and HSP90b expression levels showed an unbalanced expression of these chaperones in the liver of AIP when compared with wild-type mice. Of interest, the liver of T1 and T2 mouse strains also generated aberrant PBGD protein, while stress levels were almost identical to wild-type animals indicating mutated PBGD did not interfere with the folding machinery. Alternatively, the origin of the folding stress in the liver of AIP mice may arise from the profound deficiency in the PBGD activity which could translate into limited heme synthesis (28) and/or the accumulation of slight levels of porphyrin precursors (29) . Livers from AIP mice also presented ER stress as measured by increased sXBP1 expression when compared with wildtype mice. This finding highlights the fact that PBGD deficiency not only affects heme synthesis in hepatocytes during the acute attack but also determines a situation of chronic folding stress, where protein homeostasis is compromised both at the cytosol and the ER. Nevertheless, treatment of these mice with HDA-hPBGD normalized the levels of these chaperones and of ER stresses signaling. When the vector was injected intravenously, a transient increase in HSP70, HSP90b and sXBP1 was observed in the liver of AIP mice independently of the dose administered. These results reduce the possibility that over-expression of the transgenic protein was the origin; because the enzymatic activity reached in both groups was significantly different but stress levels were similar. Another option could be that the HDA vector produces cytoplasmic and endoplasmic stress, as has been described for other viruses (38) (39) (40) . However, HDA vectors did not synthesize any protein other than PBGD and did not enter the ER during infection. In addition, obtaining the same cytoplasmic stress with different doses rejects the option of the capsid as cause, since there is no dose -response correlation. In fact, no cytoplasmic or ER stress was observed when mice were injected directly in the liver with the same dose. Different groups have demonstrated that HSP70 and other HSPs can bind antigenic peptides derived from viruses in response to the stress signal, translocate to the plasma membrane and participate in their presentation (41, 42) . Consequently, innate and adaptive immune responses against transduced cells are activated. Our results suggest that an immunological signal through HSP70 is activated only when the vector is i.v. injected and therefore the low immunogenicity of the IH injection could be associated with this event.
In conclusion, sustained expression of hPBGD by means of intrahepatic injection of HDA vectors is a suitable treatment for patients with AIP. In addition, these data demonstrate for the first time that over-expression of PBGD from HDA resulted in proper subcellular localization to the cytoplasm, and corrects the metabolic stress produced in the hepatocytes as a result of a serious PBGD deficiency.
MATERIALS AND METHODS
Construction of plasmids and production of HDA-hPBGD
The expression cassette encoded the optimized human cDNA of the housekeeping PBGD isoform (10) . Transgene was under the control of the liver-specific human a-1-antitrypsin promoter with regulatory sequences from the human albumin enhancer (EalbAAT promoter) and included the human PBGD polyadenylation sequence (bases 9,550 -9,655: GenBank Accession No. M95623) (10) . This cassettes was inserted into the shuttle plasmid pLPBL1-Zeo (courtesy of Dr Brendan Lee, Baylor College of Medicine, Houston, TX, USA) to obtain the pL-hPBGD plasmid. The expression cassette was then liberated by AscI digestion and introduced into the AscI site of the plasmid pDelta28E4 (43) (courtesy of Dr Philip Ng) to obtain the pHDA-hPBGD. The length of the HDA-hPBGD genome is 33.1 kb. HDA vector was produced as detailed (44) . All the experiments were performed with the same vector production that had 3.65 × 10 12 viral particles (vp) HDA-hPBGD/ml measured by spectrophotometry. Helper contamination was lower than 0.0001%. Quantification of infective units was performed in the Huh7 cell line as detailed elsewhere (45) . Specific primers for the UTR 3 ′ region of the vector were used (pPBGDfw 5
The iu/vp ratio was estimated at 1/100.
Mice strains
The murine model of AIP was generated by crossbreeding of T1 (C57BL/6-pbgd tm1(neo)Uam ) and T2 (C57BL/6-pbgd tm2(neo)Uam ) strains as described by Lindberg et al. (46) . T1 mice are generated by partial disruption in one PBGD allele. This strain exhibits PBGD activity reduced to 67%. T2 mice are generated by total disruption of PBGD allele reducing their hepatic PBGD activity to 55%. Neither of these strains accumulates porphyrin precursors after phenobarbital challenge. AIP mice exhibit 33% of normal PBGD activity resulting from disruption in one allele of PBGD (T2 mutation) and a partial disruption in the other allele (T1 mutation). Transgenic strains were kindly provided by Prof. Urs A. Meyer from the University of Basel, Switzerland. Experimental protocols were approved by the Ethics Committee of the University of Navarra (CEEA029-09), according to European Council Guidelines.
Therapeutic efficacy of HDA-hPBGD
To study the effect of the i.v. injection, male (n ¼ 10) and female (n ¼ 10) AIP mice were injected with 1.5 × 10 10 iu HDA-hPBGD/kg through the tail vein (in a total volume of 200 ml). Half of the animals from each group were sacrificed 1 month after HDA injection and the rest 2 months later. For the IH injection, a dose of 2 × 10 9 iu/kg was administered, after inhalatory anesthesia (IsoFlo; Molecular Bioproducts, CA, USA), through direct injection into the left medial lobe of male and female AIP mice in a volume of 50 ml. Another group of AIP mice was injected i.v. with the same dose. Animals were sacrificed 1 month (n ¼ 6/gender) or 3 months (n ¼ 7/gender) after HDA administration. Control male and female AIP mice (n ¼ 8/gender) were IH injected with 50 ml saline and sacrificed 1 month (n ¼ 4/gender) or 3 months (n ¼ 4/gender) after injection. Male wild-type mice (n ¼ 5) were sacrificed as a control of normal PBGD activity.
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Sample collection and determination of biochemical parameters
To overload the deficient enzymatic step and induce acute attack, animals were intraperitoneally administered with four increasing doses of phenobarbital at 24 h intervals (75, 80, 85 and 90 mg/kg body weight). After the last phenobarbital dose, animals were housed during 24 h in Metabolic Cages (reference 3600M021 BIOSIS SL Biologic Systems) in order to collect 24 h urine samples. Porphyrin precursors ALA and PBG were quantified as described elsewhere (30) .
Transgene expression and detection
Human PBGD transgene expression in different organs was measured by enzymatic activity, western blot and immunohistochemistry as previously reported (10) . Liver transduction was analyzed by real-time QPCR for detection of the 3 ′ UTR-poly A hPBGD region of the vector using the specific primers detailed above. Normalization to genomic DNA was performed using specific primers for murine GAPDH (GAPDHs:
. Detection of hPBGD and adenoviral fiber by serum neutralizing antibodies was performed by western blot. Ten micrograms of recombinant hPBGD or adenoviral capsids were resolved by 12% acrylamide gel for SDS -PAGE and transferred onto a PVDF membrane. Membranes were blocked with 5% skimmed milk in PBS containing 0.05% Tween 20 and incubated overnight at 48C with the mice serum (1:50), rabbit anti-PBGD (10) (positive control) or mouse anti-adenovirus fiber (1:1000; positive control). Blots were probed with peroxidase-conjugated goat anti-mouse IgG (1:5000; Pierce, Rockford, IL, USA) for detection of mice antibodies against PBGD or peroxidase-conjugated goat antirabbit IgG or goat anti-mouse IgG (positive controls; 1:5000 Abcam, Cambridge, UK) for 1 h at room temperature and developed with chemiluminescence reagents (ECL; PerkinElmer, MA, USA).
For PBGD detection by immunocytochemistry, 1.5 × 10 
Extraction of subcellular proteins from liver samples
Following sacrifice of the mice, liver samples from mice injected with HDA-hPBGD were taken and frozen at 2808C. A fragment of 25-50 mg of tissue from each mouse was homogenized and treated as detailed in the ProteExtractw Subcellular Proteome Extraction Kit protocol (Calbiochem, Merck. Darmstadt, Germany). Proteins from cytoplasm, organelles, nucleus and cytoskeleton were obtained and quantified. For the detection of proteins, 10 mg of sample were resolved by 12% acrylamide gel for SDS -PAGE and transferred onto a PVDF membrane. Membranes were blocked as previously described and incubated overnight at 48C with one of the specific antibodies: GAPDH antibody (Stemcell Technologies, Grenoble, France) was the cytoplasm marker. Histone H1 antibody (SantaCruz) was the nuclear marker and EGFR antibody (1:1000 pAb, 06-847 Millipore) for membrane/organelles detection. Blots were probed with peroxidase-conjugated goat anti-mouse IgG (1:5000; Pierce) or peroxidase-conjugated goat anti-rabbit IgG (1:5000 Abcam) for 1 h at room temperature and developed with chemiluminescence reagents (ECL; PerkinElmer).
MTT proliferation assay
For quantification of cell proliferation and viability, 1 × 10 4 Huh7 cells were seeded in a 96-well microplate and infected with dilutions 1:10 from 10 21 to 10 24 of HDA-hPBGD. Conditions were in triplicate. Cell proliferation was measured at 24 and 48 h after infection using the Cell Proliferation Kit I MTT (Roche Diagnostics, Manheim, Germany). Plates were measured at 550 nm in a Multiskan ascent (Thermo, Rockford, IL, USA).
Molecular analysis of cytoplasmic and ER protein folding homeostasis
Total RNA was purified from homogenized tissue samples using TRIzolw reagent (Invitrogen, Carlsbad, CA, USA). Reverse transcription with random primers was performed at 378C for 50 min using M-MLV Reverse transcriptase (Invitrogen). cDNA from the liver of female AIP, T1, T2 and wild-type mice was analyzed for HSP70 (Hsp70s : 5 ′ -TGGTGCTGACGAAGATGAAG-3 ′ ; Hsp70as: 5 ′ -AGGTCGAAGATGAGCACGTT-3 ′ ; product length: 235 bp), HSP90a (Hsp90a-s: 5
′ -GATTTGCCTTTCAAGGT GGA-3 ′ ; Hsp90a-as: 5 ′ -CCAAATCGGCTTTGTTTTGT-3 ′ ; product length: 246 bp), total XBP1 (XBP1s: 5 ′ -GCAGGTGCA GGCCCAGTTGTCAC-3 ′ ; XBP1as: 5 ′ -CCCCACTGACAG AGAAAGGGAGG-3 ′ ) and spliced XBP1 (sXBP1s: 5 ′ -CGGGT CTGCTGAGTCCGCAGCAG-3 ′ ; sXBP1as: 5 ′ -CCCCACTGA CAGAGAAAGGGAGG-3 ′ ). Endogenous mouse b-actin sequence (mbactinfw, 5
′ -CGCGTCCACCCGCGAG-3 ′ ; mbactinrv, 5
′ -CCTGGTGCCTAGGGCG-3 ′ ; product length: 193 bp) was also amplified to equalize quantity. QPCR was performed in an iQ5 real-time PCR detection system (Bio-Rad, Hercules, CA, USA) using iQ SYBR green supermix. PCR amplification conditions were as follows: 958C for 5 min, 40 cycles of 958C for 15 s, 608C for 15 s, 728C for 25 s and 808C for 10 s; and a final extension for 10 min at 728C). A melting curve was generated by raising the incubation temperature from 65 to 958C to confirm amplification specificity. The amount of each transcript was expressed according to the formula 2 (Ct b-actin-Ct gene)
, where Ct is the cycle at which the fluorescence rises appreciably above background fluorescence.
Statistical analysis
Samples were run in duplicate or triplicate. The results were expressed as the mean + SD. Comparisons between the two groups were analyzed by the non-parametric Mann -Whitney test. The null hypothesis was rejected when P-values were ,0.05 (GraphPad Prism software, Graphpad Software Inc., La Jolla, CA, USA).
